Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 23;6(2):37.
doi: 10.3390/biomedicines6020037.

Current Strategies to Enhance Anti-Tumour Immunity

Katherine W Cook  1 , Lindy G Durrant  2   3 , Victoria A Brentville  4
Affiliations
Review

Current Strategies to Enhance Anti-Tumour Immunity

Katherine W Cook et al. Biomedicines. .

Abstract

The interaction of the immune system with cancer is complex, but new approaches are resulting in exciting therapeutic benefits. In order to enhance the immune response to cancer, immune therapies seek to either induce high avidity immune responses to tumour specific antigens or to convert the tumour to a more pro-inflammatory microenvironment. Strategies, including vaccination, oncolytic viruses, and adoptive cell transfer all seek to induce anti-tumour immunity. To overcome the suppressive tumour microenvironment checkpoint inhibitors and modulators of regulatory cell populations have been investigated. This review summarizes the recent advances in immune therapies and discusses the importance of combination therapies in the treatment of cancers.

Keywords: adoptive cell transfer; checkpoint inhibition; immune modulators; immune surveillance; oncolytic viruses; vaccination.

PubMed Disclaimer

Conflict of interest statement

Lindy G. Durrant is the joint CEO of Scancell Ltd. has ownership interest (including patents) in Scancell Ltd., is a consultant/advisory board member of Scancell Ltd. All authors are employees of Scancell Ltd.

References

    1. Ichim C.V. Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J. Trans. Med. 2005;3:8. doi: 10.1186/1479-5876-3-8. - DOI - PMC - PubMed
    1. Burnet F.M. The concept of immunological surveillance. Prog. Exp. Tumor. Res. 1970;13:1–27. - PubMed
    1. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Investig. 2007;117:1137–1146. doi: 10.1172/JCI31405. - DOI - PMC - PubMed
    1. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. doi: 10.1038/35074122. - DOI - PubMed
    1. Ferradini L., Mackensen A., Genevee C., Bosq J., Duvillard P., Avril M.F., Hercend T. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J. Clin. Investig. 1993;91:1183–1190. doi: 10.1172/JCI116278. - DOI - PMC - PubMed

LinkOut - more resources